Celltrion Expands Biosimilar Market Share in Japan... Vegzelma Leads with 64%
Vegzelma Achieves 64% Market Share in Japan
Grows by 14 Percentage Points in Six Months After Surpassing the 50% Mark
Celltrion is expanding the market share of its key products in Japan's biosimilar market. While the anticancer drug Vegzelma has maintained its position as the market leader in Japan, the company's autoimmune disease product line has also retained a leading position.
According to Celltrion on May 18, referencing pharmaceutical market research firm IQVIA and local data, Vegzelma (bevacizumab) achieved a 64% market share in Japan by prescription volume as of March this year. After surpassing the 50% mark in September last year, the figure increased by 14 percentage points in about six months.
Although Vegzelma was launched in Japan at the end of 2022, about two years later than competing biosimilars, it has risen to the top of the market. In Japan, a total of five bevacizumab products, including the original drug Avastin, are competing.
Celltrion believes that Japan's Diagnosis Procedure Combination (DPC) payment system has influenced the spread of biosimilars. The system allows hospitals to improve cost efficiency by using anticancer drugs with strong price competitiveness.
Other anticancer products have also maintained their market share. Herzuma (trastuzumab) ranked first with a 76% share.
The autoimmune disease product line also continued to grow. Remsima (infliximab) recorded a 44% share, while Yuflyma (adalimumab) achieved a 19% share.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "Hancom Breaks Away from Its 36-Year Mission and Formula for Success" (Comprehensive)
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Celltrion is also accelerating the expansion of its product portfolio in Japan. Last month, the company launched Aptozuma, a tocilizumab biosimilar. In March this year, it received marketing approval from Japan’s Ministry of Health, Labour and Welfare for Omliclo, an omalizumab biosimilar, and is preparing for a launch in the second half of the year. Celltrion is also working to launch Remsima SC in Japan.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
